New insulin glargine and potential adalimumab interchangeable biosimilars

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

New insulin glargine and potential adalimumab interchangeable biosimilars

Biosimilares/Novedades | Posted 27/01/2023 0 Post your comment

The US Food and Drug Administration (FDA) awarded Eli Lilly’s Rezvoglar, an insulin glargine biosimilar, the interchangeable designation in late 2022. This means that in the US, Rezvoglar can now be substituted at the pharmacy level for the originator, Sanofi’s Lantus, without a doctor’s prescription, provided state pharmacy law permits the switch. In addition, a study revealed that Pfizer’s adalimumab biosimilar may also soon achieve this status.

Interchangeable insulin glargine
Eli Lilly’s Rezvoglar was the second insulin glargine biosimilar to be approved in the US [1]. The first insulin glargine biosimilar, Viatris and Biocon’s Semglee, was approved in June 2020 [2] and was the first biosimilar to be given interchangeable status in July 2021 [3]. Insulin glargine is a long-acting human insulin analogue indicated to improve glycaemic control in adults and paediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus [1].

FDA awarded the interchangeable status to Rezvoglar without the need for new clinical data, comparative clinical immunogenicity study nor a switching study, to be submitted to support the interchangeable tag.

Potential interchangeable adalimumab biosimilar
At the November 2022 American College of Rheumatology’s annual meeting, results related to Pfizer's biosimilar (adalimumab-afzb) were presented. These showed that the biosimilar was essentially identical to AbbVie's original version for every pharmacokinetic parameter analysed, including maximum and trough concentrations, average concentration, time to reach maximum concentration, total drug exposure over time, and others. Immunogenicity markers and adverse events profiles were also highly similar. It was noted that this is the first interchangeability study of an adalimumab biosimilar to be conducted in rheumatoid arthritis patients.

If it achieves interchangeable status, Pfizer’s biosimilar adalimumab will join Cyltezo the second biosimilar to be given interchangeable status in October 2021, as a second approved interchangeable adalimumab biosimilar [4].

FDA approves first interchangeable ranibizumab biosimilar

FDA accepts application for interchangeability of adalimumab biosimilar Abrilada

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: EE.UU. frente a Alemania y Suiza: El mercado estadounidense de biosimilares se queda atrás con precios más altos

Browse the news in the Latin American Forum!

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: EE.UU. frente a Alemania y Suiza: El mercado estadounidense de biosimilares se queda atrás con precios más altos

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. FDA approves adalimumab and insulin glargine biosimilars Yusimry and Rezvoglar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jan 27]. Available from: www.gabionline.net/biosimilars/news/fda-approves-adalimumab-and-insulin-glargine-biosimilars-yusimry-and-rezvoglar
2. GaBI Online - Generics and Biosimilars Initiative. FDA approves insulin glargine biosimilar Semglee [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jan 27]. Available from: www.gabionline.net/biosimilars/news/FDA-approves-insulin-glargine-biosimilar-Semglee
3. GaBI Online - Generics and Biosimilars Initiative. FDA approves first interchangeable insulin glargine biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jan 27]. Available from: www.gabionline.net/biosimilars/news/fda-approves-first-interchangeable-insulin-glargine-biosimilar
4. GaBI Online - Generics and Biosimilars Initiative. FDA approves adalimumab biosimilar Cyltezo as interchangable [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jan 27]. Available from: www.gabionline.net/biosimilars/news/fda-approves-adalimumab-biosimilar-cyltezo-as-interchangeable

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.